Arjun Srivastava Joins Macleods Pharmaceuticals as General Manager – Legal
Macleods Pharmaceuticals has appointed Arjun Srivastava as General Manager – Legal, strengthening the company’s in-house legal leadership. In this role, he will oversee and manage all legal functions of the organisation.
Srivastava brings extensive expertise in high-stakes litigation, dispute resolution, arbitration, corporate investigations, contract negotiations, and legal compliance. He has advised cross-functional teams across the pharmaceutical sector and handled complex matters involving significant financial exposure.
Education Background and Career Progression
Education
Arjun Srivastava holds a BBA LL.B degree from Symbiosis Law School, Pune. He is also a qualified Company Secretary from the Institute of Company Secretaries of India (ICSI).
Career Journey
Srivastava began his professional career with Chess Management Services Pvt. Ltd., where he worked in legal compliance operations. He subsequently moved into private practice, first as an Associate at India Law Alliance and then as an Associate Advocate at Desai & Diwanji, gaining experience in litigation, taxation, regulatory matters, and commercial agreements.
He transitioned in-house to Lupin, where he spent over eight years in progressively senior roles. He held positions including Legal Manager and Senior Manager – Legal before rising to Deputy General Manager – Legal, his most recent designation prior to this move. His tenure at Lupin established him as a seasoned pharmaceutical-sector legal professional.
What the Firm Said
On joining Macleods Pharmaceuticals, Arjun Srivastava said: “Thank you for the warm welcome. Look forward to working with an exceptional team as we pursue our shared goals.”
Strategic Significance
Srivastava’s appointment reflects Macleods Pharmaceuticals’ focus on reinforcing its legal and compliance governance framework. His dual qualification as a lawyer and Company Secretary, combined with over eight years of pharmaceutical in-house experience at Lupin, positions him to manage the regulatory complexity and litigation demands of a large pharmaceutical organisation. The move signals the company’s intent to consolidate senior legal talent as it pursues strategic growth.
For more partner moves and lateral updates, see Inside the Partnership.
Disclaimer: This article is for informational purposes only and is based on the details provided.
